It says 7 days OR LESS. For something that supposedly expedites the viral clearance, I would expect some benefit outside the window of prophylaxis. Additionally, many of the studies on https://c19ivm.org/ suffer from similar methodological flaws to the extent of warranting their exclusion.
Although there are some studies examining potential therapeutic mechanisms behind Ivermectin (secondary parasitic infection [1], anti-inflammatory [2], antihelminthic [4])... the overall effect size remains small [3][4]. It's important to await more quality studies to confirm and strengthen this finding, to consider any potential negatives, as well as alternative treatment methods (zinc [7], astragalus [6], CBD [5]).
If some of these mechanisms are true, you would need to start taking it BEFORE symptoms begin for ideal effects... but that may carry risks of its own.
Ivermectin drug-induced liver injury
1 Jun 2023
https://journals.co....2023.v113i6.624
Approximately 3 weeks after starting the ivermectin, she noted darkening of her urine, followed by jaundice. She presented to her family practitioner. Her nasopharyngeal COVID-19 polymerase chain reaction (PCR) swab was negative. He initiated several investigations that revealed the following (normal range in brackets): total bilirubin 129 μmol/L;[5,6] conjugated bilirubin 114 μmol/L;[5,6] alkaline phosphatase 463 (40 - 160) U/L; gamma glutamyl transpeptidase 740 (<40) U/L; alanine transaminase 1 098 (<40) U/L; aspartate transaminase 811 (<40) U/L. Her international normalised ratio was 1.3. Ultrasound of the liver was normal and all initial viral markers, including hepatitis A IgM, hepatitis B surface antigen and core IgM, and hepatitis C antibody, were negative. She was referred to us for evaluation.
We performed additional investigations that included a negative hepatitis E PCR and normal immunoglobulin levels, and autoantibodies associated with autoimmune liver disease (anti- nuclear factor, anti-smooth muscle antibody, anti-liver kidney microsome type 1 and antimitochondrial antibody) were all negative.
Given the absence of other causality, a preliminary diagnosis of ivermectin DILI was considered. We advised that she stop ivermectin, and a liver biopsy was performed.
Liver biopsy (Figs 1 and 2) demonstrated portal inflammation and interface activity. Portal triaditis with interface hepatitis comprising lymphocytes, plasma cells, histiocytes and eosinophils was evident. Mild ductular reaction with secondary ductulitis was also noted. Scattered lobular necroinflammatory foci were evident with prominent zone 3 cholestasis. The liver biopsy injury pattern was compatible with a DILI.
References
[1] Llenas-García J, del Pozo A, Talaya A, Roig-Sánchez N, Poveda Ruiz N, Devesa García C, Borrajo Brunete E, González Cuello I, Lucas Dato A, Navarro M, et al. Ivermectin Effect on In-Hospital Mortality and Need for Respiratory Support in COVID-19 Pneumonia: Propensity Score-Matched Retrospective Study. Viruses. 2023; 15(5):1138. https://doi.org/10.3390/v15051138
[2] Uematsu, T., Takano, T., Matsui, H. et al. Prophylactic administration of ivermectin attenuates SARS-CoV-2 induced disease in a Syrian Hamster Model. J Antibiot 76, 481–488 (2023). https://doi.org/10.1...429-023-00623-0
[3] Ragó, Z., Tóth, B., Szalenko-Tőkés, Á. et al. Results of a systematic review and meta-analysis of early studies on ivermectin in SARS-CoV-2 infection. GeroScience (2023). https://doi.org/10.1...357-023-00756-y
[4] Zaidi, A.K., Dehgani-Mobaraki, P. The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review. J Antibiot 75, 60–71 (2022). https://doi.org/10.1...429-021-00491-6
[5] Nguyen, L. C., Yang, D., Nicolaescu, V., Best, T. J., Ohtsuki, T., Chen, S. N., Friesen, J. B., Drayman, N., Mohamed, A., Dann, C., Silva, D., Gula, H., Jones, K. A., Millis, J. M., Dickinson, B. C., Tay, S., Oakes, S. A., Pauli, G. F., Meltzer, D. O., Randall, G., … Rosner, M. R. (2021). Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response. bioRxiv : the preprint server for biology, 2021.03.10.432967. https://doi.org/10.1...21.03.10.432967
[6] Lee, D. Y. W., Li, Q. Y., Liu, J., & Efferth, T. (2021). Traditional Chinese herbal medicine at the forefront battle against COVID-19: Clinical experience and scientific basis. Phytomedicine : international journal of phytotherapy and phytopharmacology, 80, 153337. https://doi.org/10.1...med.2020.153337
[7] Tabatabaeizadeh S. A. (2022). Zinc supplementation and COVID-19 mortality: a meta-analysis. European journal of medical research, 27(1), 70. https://doi.org/10.1...001-022-00694-z